NEW YORK, March 14 (GenomeWeb News) - Serologicals will acquire Cytomyx, a wholly owned subsidiary of Cytomyx Holdings, Serologicals said today.
"Through this acquisition, our drug-discovery business will expand their service offerings to include GPCRs, kinases, and ion channels, the top three most-important target classes today," said Serologicals president and CEO, David Dodd in a statement.
Cytomyx has 23 ion channel cell lines commercially available and more in its pipeline, said Serologicals.
Serologicals expects to complete the acquisition in the first quarter of 2006 and for the acquisition to be "slightly accretive" in fiscal year 2006.
Financial details were not provided.